LONDON/COPENHAGEN, Nov 2 (Reuters) - Global brewers AB InBev (ABI.BR) and Carlsberg (CARLb.CO) this week played down concerns among some investors that demand for weight-loss drugs may lead to a sharp drop in beer drinking.
But AB InBev Chief Executive Michel Doukeris likened the concerns to others, such as how cannabis could disrupt various sectors, which he said were often short-lived.
Some clinical trials on rodents have found treatment with GLP-1 agonists reduces alcohol consumption, eases symptoms of alcohol withdrawal and more.
AB InBev has a big U.S. business, but earns more revenue in the Middle Americas and has a large footprint in countries like Brazil.
Such emerging markets often have lower obesity rates, while weight-loss drugs are unlikely to be available or affordable there any time soon.
Persons:
Nordisk's Wegovy, Michel Doukeris, Jacob Aarup, Andersen, Moritz Kronenberger, Janus Henderson, Tom O'Hara, O'Hara, Wegovy, Emma Rumney, Jacob Gronholt, Matthew Scuffham, Alexander Smith
Organizations:
Global, AB InBev, Carlsberg, Nordisk's, InBev, Reuters, Budweiser, World Health Organization, WHO, Germany's Union Investment, Brewers, Pedersen, Thomson
Locations:
COPENHAGEN, United States, Brazil, Asia, China, Danish, U.S, London, Copenhagen